Neurohumoral Modulation During Waon Therapy in Chronic Heart Failure　― Subanalysis of Waon-CHF Study ―

• Ichiki Tomoko

  Cardiorenal Research Laboratory, Department of Cardiovascular Diseases, Mayo Clinic

• Burnett Jr John C.

  Cardiorenal Research Laboratory, Department of Cardiovascular Diseases, Mayo Clinic

• Scott Christopher G.

  Division of Biomedical Statistics and Informatics, Mayo Clinic

• Heublein Denise M.

  Cardiorenal Research Laboratory, Department of Cardiovascular Diseases, Mayo Clinic

• Miyata Masaaki

  Department of Cardiovascular Medicine and Hypertension, Kagoshima University Hospital

• Kinugawa Koichiro

  Internal Medicine II, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama

• Inoue Teruo

  Department of Cardiovascular Medicine, Dokkyo Medical University

• Tei Chuwa

  Department of Cardiovascular Medicine, Dokkyo Medical University Waon Therapy Research Institute

• WAON-CHF Study Investigators

抄録

Background:Heart failure (HF) is a disease of neurohumoral dysfunction and current pharmacological therapies for HF have not improved mortality rates, thus requiring additional new strategies. Waon therapy for HF patients may be a complementary strategy with peripheral vasodilation via nitric oxide. We hypothesized that Waon therapy would improve neurohumoral factors, such as natriuretic peptides (NP) and the renin-angiotensin-aldosterone system (RAAS) in HF. Methods and Results:Plasma samples were collected from patients enrolled in the WAON-CHF Study (Waon therapy (n=77) or control (n=73)) before and after the treatment. B-type NP (BNP), C-type NP (CNP), and aldosterone (Aldo) levels were measured by respective specific radioimmunoassays. Although clinical parameters significantly improved in the Waon group compared with the control group, BNP, Aldo, and CNP levels were not statistically different between groups. On subanalysis with patient variables, BNP levels were improved in the Waon group treated with angiotensin-converting enzyme inhibitor/angiotensin-receptor blocker or spironolactone. In addition, Aldo levels were improved in the Waon group patients with diabetes mellitus, hypertension, and inotrope use, and CNP levels were improved in Waon group patients with estimated glomerular filtration rate <60 mL/min/1.73 m². These changes were not observed in the control group. Conclusions:Waon therapy may accelerate the favorable actions of RAAS modulators in HF. (WAON-CHF Study: UMIN000006705)

収録刊行物

• Circulation Journal

  Circulation Journal 81 (5), 709-716, 2017

  一般社団法人 日本循環器学会

キーワード

• Heart failure
• Natriuretic peptides
• Renin-angiotensin-aldosterone system
• Waon therapy

詳細情報

• CRID: 1390282680085382912
• NII論文ID: 130005612069
• NII書誌ID: AA11591968
• DOI: 10.1253/circj.cj-16-1117
• ISSN: 13474820
• ISSN: 13469843
• NDL書誌ID: 028129539
• PubMed: 28202884
• Web Site: https://ndlsearch.ndl.go.jp/books/R000000004-I028129539
• Web Site: https://www.jstage.jst.go.jp/article/circj/81/5/81_CJ-16-1117/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2017381434
• 本文言語コード: en
• データソース種別:
  • JaLC
  • NDL
  • Crossref
  • PubMed
  • CiNii Articles
  • KAKEN
• 抄録ライセンスフラグ: 使用不可